Minard, V., Hartmann, O., Peyroulet, M.C., Michon, J., Coze, C., Defachelle, A.S., Lejars, O., Perel, Y., Bergeron, C., Boutard, P., Leverger, G., Stephan, J.L., Thyss, A., Chastagner, P., Couillault, G., Devalck, C., Lutz, P., Mechinaud, F., Millot, F., Plantaz, D., Rialland, X. and Rubie, H. (2000) Adverse Outcome of Infants with Metastatic Neuroblastoma, MYCN Amplification and/or Bone Lesions: Results of the French Society of Pediatric Oncology. British Journal of Cancer, 83, 973-979.
http://dx.doi.org/10.1054/bjoc.2000.1412

has been cited by the following article:

• TITLE: Neuroblastoma in Saudi Children: A Single Center Experience (2006-2014)

  AUTHORS: Zaid Al Naqib, Atif A. Ahmed, Musa Al Harbi, Fahad Al Manjomi, Zaheer Ullah Khan, Awatif Alanazi, Othman Mosleh, Walid Ballourah, Mohammed Rayis

  KEYWORDS: Children, Neuroblastoma, Saudi Arabia, Survival

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.10, September 22, 2015

  ABSTRACT: Introduction: Neuroblastoma is the most common extracranial solid tumor in childhood and survival rate has improved during the last few decades. Only a few studies, related to Neuroblastoma in Saudi Arabian children, have been performed. We report epidemiologic data and our clinical experience from the department of Pediatric Hematology Oncology (PHO), King Fahad Medical City (KFMC), Riyadh, Saudi Arabia. Method: A retrospective observational study of all patients, with diagnosis of Neuroblastoma, who attended PHO-KFMC from July 2006 to June 2014 was performed. The survival periods (overall survival and disease-free survival) and the final outcomes for patients treated and followed at KFMC were recorded. The survival data were statistically correlated with the clinical, pathological and biological features of patients and tumors and compared to national and international cohorts. Results: Eight-year data were available for the 42 patients of which 22 (52.4%) were male and 20 (47.6%) were females. Age at diagnosis ranged 0 - 91 months with a mean and median of 26.3 and 18.5 months respectively. 16 (38.1%) patients were under one year and 26 (61.9%) above 1 year of age. The event-free survival (EFS) and overall survival (OS) rates were 66.5% and 71.5% respectively. EFS and OS among those who were detecting clinical and biologic characteristics of aggressive disease and tailoring therapy, is needed.